Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume

By Roehrborn C.   Andriole G.   Boyle P.   Hofner K.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 107-107

Elsevier

Access to resources Recommend Favorite

Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

By Andriole G.L.   Kirby R.  

European Urology, Vol. 44, Iss. 1, 2003-07 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

By Roehrborn C.G.   Boyle P.   Nickel J.C.   Hoefner K.   Andriole G.   the ARIA3001 ARIA3002 and ARIA3003 Study Investigators  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 434-441

Elsevier

Access to resources Recommend Favorite

Expression pattern of the ADAMTS proteinases in human prostate cancer cell lines

By Chandrasekharan S.   Hamdy F.C.   Holen I.   Cross N.   Buttle D.J.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 60-60

Elsevier

Access to resources Recommend Favorite

Isoliquiritigenin Inhibits the Growth of Prostate Cancer

By Kanazawa M.   Satomi Y.   Mizutani Y.   Ukimura O.   Kawauchi A.   Sakai T.   Baba M.   Okuyama T.   Nishino H.   Miki T.  

European Urology, Vol. 43, Iss. 5, 2003-05 ,pp. : 580-586

Elsevier

Access to resources Recommend Favorite